Clinical Trial Update: Phase I/II Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: Dose Limiting Toxicity and Abscopal Effect. [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II trial evaluated stereotactic body radiotherapy with concurrent fixed-dose tyrosine kinase inhibitors in metastatic renal cell carcinoma, reporting …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Snippet

Sponsor: University Hospital, Ghent | Conditions: Carcinoma, Renal Cell | Phase 1, Phase 2 | Status: COMPLETED